The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Chemotherapy-induced peripheral neuropathy: bench to clinical practice

  • Kim, Eunsoo (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University)
  • Received : 2020.09.18
  • Accepted : 2020.09.20
  • Published : 2020.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TA, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 2019; 20: 1493-505. https://doi.org/10.1016/s1470-2045(19)30456-5
  2. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the populationbased PROFILES registry. J Clin Oncol 2013; 31: 2699-707. https://doi.org/10.1200/JCO.2013.49.1514
  3. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014; 155: 2461-70. https://doi.org/10.1016/j.pain.2014.09.020
  4. Sisignano M, Baron R, Scholich K, Geisslinger G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat Rev Neurol 2014; 10: 694-707. https://doi.org/10.1038/nrneurol.2014.211
  5. Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2019; 25: 6295-301. https://doi.org/10.1158/1078-0432.CCR-18-2152
  6. Li Y, North RY, Rhines LD, Tatsui CE, Rao G, Edwards DD, et al. DRG voltage-gated sodium channel 1.7 is upregulated in paclitaxel-induced neuropathy in rats and in humans with neuropathic pain. J Neurosci 2018; 38: 1124-36. https://doi.org/10.1523/JNEUROSCI.0899-17.2017
  7. Bankar G, Goodchild SJ, Howard S, Nelkenbrecher K, Waldbrook M, Dourado M, et al. Selective NaV1.7 antagonists with long residence time show improved efficacy against inflammatory and neuropathic pain. Cell Rep 2018; 24: 3133-45. https://doi.org/10.1016/j.celrep.2018.08.063
  8. Poupon L, Lamoine S, Pereira V, Barriere DA, Lolignier S, Giraudet F, et al. Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology 2018; 140: 43-61. https://doi.org/10.1016/j.neuropharm.2018.07.026
  9. Kim K, Jeong W, Jun IG, Park JY. Antiallodynic and antiinflammatory effects of intrathecal R-PIA in a rat model of vincristine-induced peripheral neuropathy. Korean J Anesthesiol 2020. doi: 10.4097/kja.19481.
  10. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxeland vincristine-induced painful peripheral neuropathy. Pain 2004; 109: 150-61. https://doi.org/10.1016/j.pain.2004.01.029
  11. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 1941-67. https://doi.org/10.1200/JCO.2013.54.0914
  12. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309: 1359-67. https://doi.org/10.1001/jama.2013.2813
  13. Fallon MT, Storey DJ, Krishan A, Weir CJ, Mitchell R, Fleetwood-Walker SM, et al. Cancer treatment-related neuropathic pain: proof of concept study with menthol--a TRPM8 agonist. Support Care Cancer 2015; 23: 2769-77. https://doi.org/10.1007/s00520-015-2642-8
  14. Anand P, Elsafa E, Privitera R, Naidoo K, Yiangou Y, Donatien P, et al. Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. J Pain Res 2019; 12: 2039-52. https://doi.org/10.2147/JPR.S213912
  15. Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, et al. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest 2018; 128: 816-25. https://doi.org/10.1172/jci96160
  16. Stockstill K, Doyle TM, Yan X, Chen Z, Janes K, Little JW, et al. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J Exp Med 2018; 215: 1301-13. https://doi.org/10.1084/jem.20170584
  17. Kim E, Hwang SH, Kim HK, Abdi S, Kim HK. Losartan, an angiotensin II type 1 receptor antagonist, alleviates mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain by inhibiting inflammatory cytokines in the dorsal root ganglia. Mol Neurobiol 2019; 56: 7408-19. https://doi.org/10.1007/s12035-019-1616-0
  18. Yin M, Kim YO, Choi JI, Jeong S, Yang SH, Bae HB, et al. Antinociceptive role of neurotensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy. Korean J Pain 2020; 33: 318-25. https://doi.org/10.3344/kjp.2020.33.4.318
  19. Hait WN. Translating research into clinical practice: deliberations from the American Association for Cancer Research. Clin Cancer Res 2005; 11: 4275-7. https://doi.org/10.1158/1078-0432.CCR-05-0321